Company intelligence / Profile preview

Logical Arts

Waltham, Massachusetts, United Stateslogicalarts.net ↗

Ownership: Private
Development stage: Other

Overview

Logical Therapeutics developed LT-NS001, a novel pro-drug of naproxen designed to reduce gastrointestinal toxicity while maintaining anti-inflammatory efficacy. Early clinical studies demonstrated improved GI safety compared to conventional naproxen, achieving key milestones and financing rounds at that time.

Therapeutic areas: GastroenterologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Logical Arts.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Logical Arts.

Explore the full profile